$2,995.00
Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that could radically change how certain diseases are treated.
Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that could radically change how certain diseases are treated. The precision and rapid-acting fashion of tools such as zinc-finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) create untapped opportunity. But gene editing does not come without challenges and controversy, especially when it comes to safety and ethical issues.
Key academic research performed over the past 20 years has led to important discoveries in CRISPR/Cas9 technology, and has also prompted a fierce intellectual property battle over which organization owns the foundational patents. Nevertheless, out of that research has come a wave of start-up companies that are inching toward commercial clinical development with gene editing therapy candidates. Along the way, these biotechs have secured partners, including large pharmaceutical companies, to advance development and eventually commercialization.
CONTENTS
6 EXECUTIVE SUMMARY
6 Gene editing technologies evolve and improve over time
6 Multiple researchers have contributed to key academic discoveries in CRISPR/Cas9
6 The dispute over foundational CRISPR/Cas9 patents carries on
7 Many challenges and controversies remain in advancing CRISPR/Cas9 technology
7 Many players, from small biotechs to Big Pharma, are developing gene editing drug candidates
8 The gene editing pipeline is a small proportion of regenerative medicine therapies, and is dominated by CRISPR/Cas9
9 EVOLUTION OF GENE EDITING TECHNOLOGY
9 Gene editing can radically change how diseases are targeted
9 Gene editing is an emerging modality within the broader regenerative medicine market
10 Zinc-finger nucleases
12 Transcription activator-like effector nucleases
14 CRISPR/Cas9
17 Bibliography
20 ORIGINS OF ACADEMIC RESEARCH IN CRISPR/CAS9
20 Academic research over the last 20 years has helped to advance CRISPR/Cas9 technology toward human therapeutic use
21 Many start-ups have been borne out of CRISPR/Cas9 academic research
22 Bibliography
24 CRISPR/CAS9 PATENT LITIGATION
24 Select key patent filings, issuances, and decisions
27 Patent pools and cross-licensing may help commercial drug developers avoid intellectual property barriers in the future
28 Bibliography
31 CHALLENGES AND CONTROVERSIES WITH GENE EDITING
31 Process challenges exist for gene editing tools
32 Editing human embryos pose ethical concerns
33 Safety issues plague gene editing
33 As is the case with many regenerative medicines, cost of gene editing therapies may be prohibitive
34 Bibliography
36 KEY COMPANIES IN GENE EDITING
36 Key players in gene editing span both biotech and large pharma companies
36 Profiles of select key gene editing companies
48 Through deal-making, large pharmaceutical companies have gotten involved in gene editing
52 Bibliography
54 GENE EDITING PIPELINE TRENDS
54 CRISPR/Cas9 gene editing candidates represent the majority of the gene editing pipeline
54 ZFN therapies are the most advanced by phase
55 Rare diseases lead gene editing therapy areas
57 CRISPR/Cas9 is now being tested in humans
58 Editas and Intellia are on deck to initiating CRISPR/Cas9 Phase I trials
58 Bibliography
60 APPENDIX
60 Scope
60 Methodology
LIST OF FIGURES
11 Figure 1: Zinc finger nuclease gene editing tool
12 Figure 2: Zinc-finger nuclease advantages and disadvantages
13 Figure 3: Transcription activator-like effector nuclease gene editing tool
14 Figure 4: Transcription activator-like effector nucleases advantages and disadvantages
17 Figure 5: CRISPR/Cas9 gene editing tool
17 Figure 6: CRISPR/Cas9 advantages and disadvantages
20 Figure 7: Timeline of select key academic research discoveries in CRISPR/Cas9 as it has evolved toward human therapeutic use, 1987–2013
24 Figure 8: Timeline of select key patent actions in CRISPR/Cas9 technology, 2012–17
31 Figure 9: Key challenges and controversies with gene editing
36 Figure 10: Editas Medicine and CRISPR Therapeutics lead the most active gene editing companies
54 Figure 11: CRISPR/Cas9 technology dominates the gene editing pipeline, preclinical–Phase II*
55 Figure 12: First-generation ZFN technology leads to more advanced candidates in the gene editing pipeline
56 Figure 13: Rare diseases are most often targeted by gene editing candidates
57 Figure 14: Gene editing pipeline volume by indication
LIST OF TABLES
9 Table 1: Overview of gene editing technologies
22 Table 2: CRISPR/cas9 start-up company academic origins
38 Table 3: Key gene editing companies
42 Table 4: Cellectis’ gene editing pipeline
43 Table 5: CRISPR Therapeutics’ gene editing pipeline
45 Table 6: Editas Medicine’ gene editing pipeline
46 Table 7: Intellia Therapeutics’ gene editing pipeline
47 Table 8: Sangamo Therapeutics’ gene editing pipeline
49 Table 9: Key gene editing deals involving large pharmaceutical companies, 2012–17*
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!